Small molecule · Inhibitor of aldosterone synthase (CYP11B2) · developed by Astrazeneca
Baxdrostat is an oral inhibitor of aldosterone synthase, the enzyme that produces aldosterone, with higher potency and selectivity for it than for 11β-hydroxylase, the final enzyme in cortisol synthesis. By lowering aldosterone, it reduces sodium and water retention and blood pressure. It is studied in hypertension, including uncontrolled and resistant hypertension, and in hypertension with chronic kidney disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 7, 2026). Read the full label for the exact wording, limitations and safety information.
Chronic Kidney Disease and HypertensionResistant HypertensionUncontrolled Hypertension
Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →